Current Research Experimental Vascular Medicine

The department of Experimental Vascular Medicine focuses on basal and translational research in cardiometabolic diseases. The overall aim is to understand the (epi)genetic, molecular and cellular pathophysiology of these disorders and to translate this knowledge into clinical applications such as diagnostic and prognostic biomarkers and novel treatments. The research program is conducted by 5 independent project leaders (30 PhD students and 4 postdocs) in close collaboration with a large network of internal, national and international partners. With an output of more than 300 peer-reviewed publications over the last 5 years and very successful external funding, the Department of Experimental Vascular Medicine has gained a broad range of expertise in three main research lines:

1. Lipid Metabolism and Insulin Resistance

Disturbances in lipid and triglyceride metabolism are a major cause in the increased risk in the development of cardiovascular diseases. The research of the department is focused on known and unknown genes which play a role in the homeostasis of the lipid metabolism and can be dissected in two main research lines: 1) The effects of (functional) mutations in candidate genes and 2) the identification of new genes. To visualize the physiological role of mutations and or novel genes an extensive toolbox of functional tests is available including studies with cultured cells as well as lipid flux measurements using stable isotope based technologyBoth research lines are mainly based on the investigation of the incidence of cardiovascular diseases in families at risk. This is feasible by the availability of genetic fieldworkers and nurses who collect the information of the family history and biomaterials at each individual family member. The work is conducted in close collaboration with the department of Vascular Medicine.


Dr. Geesje Dallinga,, Tel: +31(0)205661150 (Publications)

Prof. dr. Kees Hovingh,, Tel: +31(0)205665993 (Publications)

2. Obesity, metabolic syndrome and Type 2 diabetes

Our group focuses on underlying causal mechanisms in the progression of obesity to type 2 diabetes and its cardiovascular comorbidity. This research line is human centered and conducted using a cohort of bariatric surgery patients (collaboration Slotervaart ziekenhuis) and a large multiethnic HELIUS cohort. Computational modelling and machine learning on multi-omics data sets is carried out to visualize disease trajectories. Special interest focuses on the role of gutmicrobiota in causing cardiometabolic disease. We aim to find novel pathophysiological pathways driving dyslipidemia and insulin resistance and their hierarchical clustering in driving chronic adipose tissue, liver (NASH) and macrovascular inflammation. Identification of novel diagnostic and therapeutic targets ( for instance, inhibiting bacterial metabolite production and/or replenishing novel beneficial bacterial strains) may lead to a more personalized medicine treatment for cardiometabolic disease.


Prof. dr. Max Nieuwdorp,, Tel : +31(0)205662824 (Publications)

Prof. dr. Bert Groen,, Tel : +31(0)205668589 (Publications)

Prof. dr. Natal van Riel,, Tel : +31(0)205668589 (Publications)

Dr. Evgeni Levin, ,Tel: +31(0)205668589 (Publications)

3. Hemostasis and Thrombosis

The blood coagulation system is an essential host defense mechanism. Better insights in blood platelets, the (regulation of the) coagulation system and fibrinolysis have lead and will lead to new risk factors for venous thrombosis and to targets for therapy for venous and arterial thrombosis. In the light of this scope a number of research-lines are being explored.


Prof. dr. Joost Meijers,,Tel: +31(0)205662825 (Publications)

Back to EVG


Postbox 22660
1100 DD Amsterdam

+31(0)20 5662824

Principal Investigators:

Prof Dr. M. Nieuwdorp, MD

Prof Dr. A.K. Groen

Prof. Dr. J.C.M. Meijers

Prof. Dr. Ir . N. van Riel

Dr. Ir. G.M. Dallinga-Thie